Clinical trials: ifosfamide
Soft Tissue Sarcoma
Efficacy and Safety of Envafolimab Plus Doxorubicin and Ifosfamide for Advanced Soft Tissue Sarcoma
Soft tissue sarcoma (STS) is a rare, highly heterogeneous malignancy with a poor prognosis. The standard first-line treatment for advanced patients is anthracyclines (doxorubicin, A) combined with ifosfamide (I, AI regimen), but…
- Trial name
- NCT07243626
- Testing
- Envafolimab combined with an AI regimen (doxorubicin and ifosfamide)
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Penile Cancer
Neoadjuvant Chemotherapy for Patients With Squamous Cell Carcinoma of the Penis
Primary Objective: -To evaluate the feasibility and efficacy of multimodality treatment (neoadjuvant chemotherapy prior to extirpative surgery) for clinical stage TXN2-3M0 squamous cell carcinoma of the penis.
- Trial name
- NCT00512096
- Testing
- Ifosfamide, Paclitaxel (Taxol), Cisplatin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
B-cell Non Hodgkin Lymphoma
A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
The Glo-BNHL trial is trying to find better medicines for children and young people with B-cell non-Hodgkin Lymphoma (B-NHL) that does not go away (refractory B-NHL) or does but comes back again (relapsed B-NHL).
- Trial name
- Glo-BNHL (NCT05991388)
- Testing
- Odronextamab, Loncastuximab tesirine, Rituximab
- Where
- 11 sites in Australia, Austria and 5 more
- Volunteers
- 210 people
- Sponsor
- University of Birmingham
Sarcoma, Soft Tissue
Neoadjuvant Adriamycin and Ifosfamide Plus High-Dose ICE in Patients With Soft Tissue Sarcoma (STS)
Complete resection is still the only curative treatment option in patients with soft tissue sarcoma (STS). Patients with a non-resectable STS have a dismal prognosis even without evidence of metastatic disease.
- Trial name
- NCT00204646
- Testing
- Adriamycin, Ifosfamide, Etoposide
- Where
- Germany
- Sponsor
- University Hospital Tuebingen
Sarcoma
Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal Tumor
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00006734
- Testing
- filgrastim, cyclophosphamide, doxorubicin hydrochloride
- Where
- 239 sites in United States, Australia and 5 more
- Volunteers
- 587 people
- Sponsor
- Children's Oncology Group
Non-Small-Cell Lung Carcinoma
Randomized Phase III-Study in Stage IIIb and IV Non-Small-Cell Lung Cancer. Sequential Single-Agent vs. Double-Agent vs. Triple-Agent Therapy.
This study wants to assess different intensive therapy sequences for the treatment of non-small-cell lung cancer. It claims less on the efficacy of different chemotherapy combinations, than more on the comparison of different…
- Trial name
- NCT00148395
- Testing
- Gemcitabine, Navelbine, Carboplatin
- Where
- Germany
- Volunteers
- 280 people
- Sponsor
- Aktion Bronchialkarzinom e.V.
Neoplasms, Solid Tumors
A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)
This is a Phase 1/1B, non-randomized, open-label, dose-escalation study of robatumumab (SCH 717454, MK-7454) administered in combination with chemotherapy in pediatric participants with solid tumors, to be conducted in…
- Conditions
- Neoplasms, Solid Tumors, Bone Cancer, Kidney Tumor
- Trial name
- NCT00960063
- Testing
- Temozolomide, Vincristine, Ifosfamide
- Volunteers
- 4 people
- Sponsor
- Merck Sharp & Dohme LLC
T-lymphoblastic Lymphoma, Relapsed Disease
Venetoclax Plus IM2 Regimen for Relapsed and Refractory T Lymphoblastic Lymphoma/Leukemia
To evaluate the safety and efficacy of Venetoclax plus IM2 regimen for relapsed and refractory T lymphoblastic lymphoma/leukemia.
- Conditions
- T-lymphoblastic Lymphoma, Relapsed Disease, Refractory Lymphoma, Refractory Leukemia
- Trial name
- NCT05576532
- Testing
- BCL2 Inhibitor plus IM2 regimen
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma
This phase II trial tests how well epcoritamab in combination with standard of care (SOC) platinum-based chemotherapy (rituximab, ifosfamide, carboplatin, etoposide [RICE], rituximab, cytarabine, dexamethasone, oxaliplatin or…
- Conditions
- Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements, Recurrent High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements
- Trial name
- NCT06905509
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Carboplatin, Cytarabine
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of California, Davis
Hodgkin Lymphoma
PET-Adapted Low-Dose Nivolumab With NICE-40 for Relapsed/Refractory Classical Hodgkin Lymphoma
Nivolumab is an anti-PD-1 antibody with high activity in patients with relapsed/refractory classical Hodgkin lymphoma (r/r cHL).
- Trial name
- NICE-40 (NCT04981899)
- Testing
- Nivolumab, Ifosfamide, Carboplatin
- Where
- 5 sites in Russia
- Volunteers
- 37 people
- Sponsor
- St. Petersburg State Pavlov Medical University
Prostatic Neoplasm
Observation Study to Evaluate the Efficacy and Safety of Ifosfamide/Mesna in Patients With Metastatic Castration-resistant Prostate Cancer
Prostate cancer is the 2nd most common cancer in men worldwide. Based on the results of several recent clinical trials, systemic treatments including hormone inhibitors, docetaxel, cabazitaxel, and PARP inhibitors are being used…
- Trial name
- NCT06236789
- Testing
- Ifosfamide/mesna
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Yonsei University
Locally Advanced Soft Tissue Sarcoma
A Prospective, Single-arm, Multicenter Exploratory Clinical Study of Anlotinib Combined With Bempegaldesleukin and Conventional Chemoradiotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Soft Tissue Sarcoma.
This study employs a multicenter, single-arm trial design. Participants will receive a treatment regimen consisting of "anlotinib plus bempegaldesleukin concurrent with radiotherapy," followed by a maintenance therapy phase of…
- Trial name
- NCT07156643
- Testing
- Anlotinib and bempegaldesleukin
- Where
- China
- Volunteers
- 46 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Thrombocytopaenia
Dose Finding Study Of Oral Eltrombopag In Patients With Sarcoma Receiving Adriamycin And Ifosfamide
The study will evaluate the safety and tolerability, optimal biologic dose, and pharmacokinetics of eltrombopag for patients with advanced sarcoma who have a low platelet count and are receiving ADRIAMYCIN and ifosfamide (AI)…
- Trial name
- NCT00358540
- Testing
- eltrombopag
- Where
- 7 sites in United States
- Volunteers
- 18 people
- Sponsor
- GlaxoSmithKline
Soft Tissue Sarcoma
Apatinib Mesylate Combined With Doxorubicin and Ifosfamide in Advanced Soft-tissue Sarcoma
Apatinib mesylate is a multitarget receptor tyrosine kinase inhibitor. This trial is to evaluate the efficacy and safety of apatinib mesylate combined with doxorubicin and ifosfamide in the treatment of advanced soft tissue…
- Trial name
- NCT04012827
- Testing
- Apatinib Mesylate, doxorubicin, ifosfamide
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Sun Yat-sen University
Non-Hodgkin's Lymphoma, B-cell Lymphoma
Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide
Primary objective of the study is to determine the maximum tolerated dose (MTD) of bortezomib (Velcade) in combination with rituximab, ifosfamide, carboplatin and etoposide for adult patients with relapsed or refractory…
- Trial name
- V-RICE (NCT01300793)
- Testing
- Velcade (bortezomib), rituximab, ifosfamide, carboplatin, etoposide
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of California, San Francisco
Carcinoma, Non-Small-Cell Lung
Randomised Study Comparing Three Chemotherapy Regimens in Non-small Cell Lung Cancer
The purpose of this study is to determine if cisplatin-based chemotherapy, cisplatin-gemcitabine-ifosfamide or cisplatin-docetaxel, will improve survival in comparison to the combination gemcitabine-ifosfamide in patients with…
- Trial name
- NCT00622349
- Testing
- Cisplatin, Ifosfamide, Gemcitabine, Ifosfamide, Gemcitabine, Cisplatin, docetaxel
- Where
- 4 sites in Belgium, France and 2 more
- Volunteers
- 707 people
- Sponsor
- European Lung Cancer Working Party
Solid Tumors
Topotecan, Ifosfamide and Carboplatin in Children and Young Adults With Solid Tumors
Primary Objectives: To determine the maximum tolerated dose (MTD) of Topotecan when added to a fixed dose regimen of Ifosfamide and Carboplatin in children and young adults with solid tumors.
- Trial name
- NCT00502892
- Testing
- Topotecan, Ifosfamide, Carboplatin
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
This phase II/III trial is studying the side effects and how well giving dasatinib together with combination chemotherapy works in treating young patients with newly diagnosed acute lymphoblastic leukemia (ALL).
- Conditions
- Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
- Trial name
- NCT00720109
- Testing
- Asparaginase, Cyclophosphamide, Cytarabine
- Where
- 134 sites in United States, Australia and 3 more
- Volunteers
- 63 people
- Sponsor
- National Cancer Institute (NCI)
Soft Tissue Sarcomas
Study on the Treatment of Soft Tissue Sarcoma With First-line Chemotherapy Failure by Anrotenil Hydrochloride Capsule
Soft tissue sarcoma STS is a group of malignant tumors derived from connective tissue other than bone and cartilage. It can occur in any part of the body at any age, and there is no significant gender difference.According to…
- Trial name
- NCT04223583
- Testing
- Anlotinib Hydrochloride
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Henan Cancer Hospital
Sarcoma, Fibrosarcoma
Hypofractionated Radiotherapy With Sequential Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall
After a screening, which consists of biopsy, physical examination, initial diffusion-weighted magnetic resonance imaging (DWI-MRI), body computed tomography (CT) scan, blood tests and case analysis on Multidisciplinary Team (MDT)…
- Conditions
- Sarcoma, Fibrosarcoma, Leiomyosarcoma, Liposarcoma
- Trial name
- UN-RESARC (NCT03651375)
- Testing
- Sequential chemotherapy - 3 courses of AI, Hypofractionated radiotherapy
- Where
- Poland
- Volunteers
- 46 people
- Sponsor
- Maria Sklodowska-Curie National Research Institute of Oncology